West Virginia Medicaid Managed-Care Rebates Associated With Physician-Administered Drugs
Learn how the AI-generated research projects were createdOverall Conclusion
The Office of Inspector General found that West Virginia did not invoice manufacturers for some rebates due on physician-administered drugs dispensed to enrollees of Medicaid managed-care organizations during the audit period, totaling $8.2 million ($6.1 million Federal share). Internal controls did not consistently ensure data were used to invoice rebates. The WV Bureau for Medical Services took corrective actions, including system changes and re-processing of claims for rebate invoicing in 2025, but the OIG maintained its recommendations and will consider them implemented when the funds are refunded.
Source Document
Audit Scope
Audit period January 1, 2019 through December 31, 2022; reviewed physician-administered drug claims paid by West Virginia Medicaid Bureau for Medical Services’ managed-care organizations; used CMS top-20 multiple-source drug lists, CMS Medicaid Drug Rebate File, and Medicaid Drug Product File to classify drugs as single-source or top-20 multiple-source; evaluated data collection and invoicing processes.
Key Findings Summary
The State agency did not invoice for, and collect from manufacturers, estimated rebates totaling $8.2 million ($6.1 million Federal share) for physician-administered drugs dispensed to MCO enrollees.
Although the State agency’s policies required the collection of drug utilization data necessary to invoice for rebates on all physician-administered drug claims, the State agency’s internal controls did not always ensure that the collected data were used to invoice manufacturers and collect rebates for physician-administered drugs dispensed to MCO enrollees.
In 2019, the State agency’s fiscal agent updated its rebate administration system; however, during the audit period the State agency did not receive all of the necessary information to invoice and collect rebates from the drug manufacturers.
AI-Assisted
AI Scope Summary
This audit evaluated whether West Virginia’s Bureau for Medical Services properly invoiced manufacturers for rebates on physician-administered drugs dispensed to Medicaid managed-care organization enrollees during 2019–2022, found non-invoiced rebates totaling about $8.2 million (including $6.1 million Federal share) due to data gaps and limited system functionality, and recommended refunds to the Federal Government along with actions to expand rebate-eligible HCPCS code coverage for future periods.
AI-Generated Insight
This audit highlights gaps in WV's Medicaid rebate invoicing for physician-administered drugs, with potential Federal revenue recovery and ongoing improvements to data capture and rebate processing.
Audit Objectives
Determine whether the State agency complied with Federal Medicaid requirements for invoicing manufacturers for rebates for physician-administered drugs dispensed to Medicaid managed-care organization enrollees.
Audit Findings (3)
The State agency did not invoice for, and collect from manufacturers, estimated rebates totaling $8.2 million ($6.1 million Federal share) for physician-administered drugs dispensed to MCO enrollees.
Although the State agency’s policies required the collection of drug utilization data necessary to invoice for rebates on all physician-administered drug claims, the State agency’s internal controls did not always ensure that the collected data were used to invoice manufacturers and collect rebates for physician-administered drugs dispensed to MCO enrollees.
In 2019, the State agency’s fiscal agent updated its rebate administration system; however, during the audit period the State agency did not receive all of the necessary information to invoice and collect rebates from the drug manufacturers.
Recommendations (2)
Refund to the Federal Government $6,055,786 (Federal share) for claims for single-source physician-administered drugs that were ineligible for Federal reimbursement.
Refund to the Federal Government $22,718 (Federal share) for claims for top-20 multiple-source physician-administered drugs that were ineligible for Federal reimbursement.